Study Evaluating Sirolimus in Kidney Transplant Recipients in India
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
13 Years and older (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients in End Stage Renal Disease who are above 13 years of age and weigh more than 40 kilograms.
Patients scheduled to receive a kidney from a cadaveric donor, from a living unrelated donor or from a living related donor.
Evidence of major infections at the time of sirolimus administration
Use of any investigational drug or treatment up to 4 weeks prior to enrolling in the study and during the treatment phase.
Females who are pregnant, breast feeding or in reproductive age group and not using a medically acceptable form of contraception